For the three months ended Jan. 31, the firm's revenues rose to $1.36 billion from $1.28 billion, beating analysts' average estimate of $1.35 billion.
The team anticipates launching its first clinical diagnostic assay, which will detect targeted, low-frequency genetic mutations in lung cancer, in 2021.
The researchers will use Agilent's Fourier-transform infrared spectroscopy technology to monitor infants and determine those at highest risk of developing atopic eczema.
Abbott highlighted its next-generation Alinity platforms, and Caris discussed its plans to provide precision oncology services.
While it continues to seek investments, the firm is also making preparations for an initial public offering on the Nasdaq First North exchange.
The British molecular diagnostics company received a CE-IVD mark for the assay, called BCA-1, in June, and launched the test in October.
The firm's diagnostics and genomics group saw a 5 percent year-over-year revenue increase in the fourth quarter.
Clinicians can use the PD-L1 IHC 22C3 pharmDx assay to help identify head and neck squamous cell carcinoma patients for treatment with Merck's Keytruda in Europe.
Due out in December, the Magnis automated library prep instrument is meant to be an affordable and easy way for researchers to use Agilent's SureSelect kits.
Akadeum is currently developing a tool that involves microbubbles to deplete background molecules from circulating tumor cells in liquid biopsies.